No saved knowledge topics matched, so I'll research this from public sources directly. Since hedweb.com is the Hedonistic Imperative site, I'll survey recent (2024–2026) science across its core themes: hedonic set-point genetics, gene therapy, novel analgesics, cultured meat, DBS/wireheading, germline editing, wildlife suffering, and animal sentience.

Good — strong results on analgesics, DBS, gene therapy, cultured meat, and prime editing. Now a second batch covering the site's other core themes.

Two strong batches so far. One final batch on well-being genomics, embryo screening, AI-designed drugs, CNS gene editing, and wild-animal welfare.

I have comprehensive material across all of the site's core themes. Now let me load the canvas skill and compile the report.

Now I'll write the full report as a canvas.

The full research brief is now open in the canvas "HedWeb: 10 Key Scientific Updates (2024–2026)". Here are the ten updates in brief:

1. Non-opioid analgesics are now clinical reality — FDA approved suzetrigine (Journavx), the first NaV1.8-inhibitor analgesic, in Jan 2025 with no addiction signal ( Nature Biotechnology,  Anesthesiology); Kyoto's ADRIANA offers a second mechanism in trials ( PNAS).
2. Pain-channel genetics is maturing — new SCN9A congenital-insensitivity variants were functionally characterized ( Pain), and a UK Biobank study found many "painful" channel variants have no population phenotype — a nuance for the pain-free-genome arguments ( Brain).
3. Precision psychiatry's first genetic-biomarker success — ENLIGHTEN showed liafensine works in ANK3-positive treatment-resistant depression ( JAMA Psychiatry).
4. First non-dopaminergic antipsychotic in ~70 years — Cobenfy (KarXT) approved Sept 2024 ( FDA,  Nat Rev Drug Discov).
5. Psilocybin passed phase 3 — COMP005 and COMP006 both hit endpoints with 26-week durability ( Compass), though the independent EPISODE trial missed its primary endpoint — sharpening the recalibration-vs-peak-experience debate ( JAMA Psychiatry).
6. Wireheading sections can cite human data now — randomized DBS trials and a 172-patient pooled analysis show durable remission in treatment-resistant depression ( Brain Stimulation,  Brain Stimulation).
7. Genome editing leapt forward — minimal-error prime editors, disease-agnostic suppressor-tRNA editing, and in-vivo base editing in the brain ( Nature,  Nature,  Nat Biomed Eng).
8. Gene drives suppressed real malaria in Tanzania (Nature, Dec 2025) — though Burkina Faso's trial halt is the governance counterpoint ( Nature,  Innovation Report).
9. Sentience and wild-animal-welfare science mainstreamed — refined precautionary frameworks including insects, a new LSE animal-sentience centre, and peer-reviewed treatments of the anti-wildlife-suffering movement ( Animal Welfare,  LSE,  Oryx).
10. Cultured meat's decade of mixed reality — 2025 approvals and first US retail sales, versus seven state bans, closures, and new UK regulatory guidance ( Vireo Advisors,  PPTI News).

The biggest single takeaway: the site's most distinctive claim — engineering pain-free, better-than-well lives — now has its strongest-ever evidence base (marketed non-addictive analgesics, precision psychiatry, and clinical brain stimulation). The canvas includes a full source table with credibility ratings, open questions, and suggested page-level edits.